# Maximizing Success: An Overview of Optimizing the Ovarian Tissue Transplantation Site

**Authors:** Koray Görkem Saçıntı, Rowaida Sadat, Sinan Özkavukçu, Meltem Sonmezer, Murat Sönmezer

PMC · DOI: 10.5935/1518-0557.20240027 · JBRA Assisted Reproduction · 2024-07-01

## TL;DR

This paper reviews the best practices and considerations for ovarian tissue transplantation, focusing on optimizing the site for successful outcomes.

## Contribution

The paper provides a comprehensive review of the advantages and disadvantages of different ovarian tissue transplantation sites.

## Key findings

- Optimal surgical techniques and sites for ovarian tissue transplantation have been identified.
- Retroperitoneal and preperitoneal sites are highlighted for their viability and efficacy.
- Strategies to reduce ischemic injury during transplantation are discussed.

## Abstract

Ovarian tissue cryopreservation and transplantation (OTCT) has emerged in recent
years as a potential method for reversing abnormal endocrine and reproductive
functions, particularly in patients receiving gonadotoxic cancer treatments
having longer survival rates. From its first rodent experiments to human trials,
OTCT has evolved tremendously, opening new windows for further utilization.
Since then, significant progress has been achieved in terms of techniques used
for surgical removal of the tissue, optimal fragment size, freezing and thawing
procedures, and appropriate surgical sites for the subsequent reimplementation
of the graft. In addition, various approaches have been proposed to decrease the
risk of ischemic injury, which is the leading cause of significant follicle loss
during neo-angiogenesis. This review aims to discuss the pros and cons of
ovarian and retroperitoneal transplantation sites, highlighting the
justifications for the viability and efficacy of different transplantation sites
as well as the potential advantages and drawbacks of retroperitoneal or
preperitoneal area.

## Full-text entities

- **Diseases:** ischemic injury (MESH:D017202), gonadotoxic cancer (MESH:D009369)
- **Species:** Homo sapiens (human, species) [taxon 9606], Rodentia (rodent, order) [taxon 9989]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11349257/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC11349257/full.md

## References

51 references — full list in the complete paper: https://tomesphere.com/paper/PMC11349257/full.md

---
Source: https://tomesphere.com/paper/PMC11349257